×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at 2013 European Cancer Congress

Results from studies of marketed and pipeline products will be presented at the 2013 European Cancer Congress (ECCO), happening Sept. 27 to Oct. 1 in Amsterdam.

Abstracts are available on the European Cancer Congress website at eccamsterdam2013.ecco-org.eu .

If you are at ECCO, stop by Amgen's booth #2300 to learn more about Amgen Oncology.

Follow Amgen on Twitter at twitter.com/amgen to receive news updates during ECCO.


Sep. 30, 2013

News Release: Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

Sep. 28, 2013

News Release: Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival

Sept. 12, 2013

News Release: Amgen Highlights Data to be Presented at 2013 European Cancer Congress